SALARIUS PHARMACEUTICALS INC (SLRX) Stock Price, Forecast & Analysis
USA - NASDAQ:SLRX - US79400X5032 - Common Stock
SLRX Key Statistics, Chart & Performance
The current stock price of SLRX is 2.44 USD. In the past month the price decreased by -40.2%. In the past year, price decreased by -89.16%.
SLRX Latest News, Press Relases and Analysis
SLRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About SLRX
Company Profile
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
Company Info
SALARIUS PHARMACEUTICALS INC
2450 Holcombe Blvd Ste J-608
Houston TEXAS 77021 US
CEO: David J. Arthur
Employees: 2
Phone: 13467720346
SALARIUS PHARMACEUTICALS INC / SLRX FAQ
Can you describe the business of SALARIUS PHARMACEUTICALS INC?
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2015-01-29. The firm is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
What is the stock price of SALARIUS PHARMACEUTICALS INC today?
The current stock price of SLRX is 2.44 USD. The price decreased by -13.48% in the last trading session.
Does SLRX stock pay dividends?
SLRX does not pay a dividend.
How is the ChartMill rating for SALARIUS PHARMACEUTICALS INC?
SLRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the next earnings date for SLRX stock?
SALARIUS PHARMACEUTICALS INC (SLRX) will report earnings on 2025-11-12, after the market close.
Can you provide the ownership details for SLRX stock?
You can find the ownership structure of SALARIUS PHARMACEUTICALS INC (SLRX) on the Ownership tab.
SLRX Technical Analysis
SLRX Financial Highlights
Over the last trailing twelve months SLRX reported a non-GAAP Earnings per Share(EPS) of -48.74. The EPS increased by 74.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -366.41% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |